Zoledronic acid inhibits osteosarcoma growth in an orthotopic model

Zoledronic acid (ZOL) has been shown to reduce osteolysis in bone metastasis. Its efficacy in osteosarcoma has not been convincingly proved in a clinically relevant model for the disease. In vitro , ZOL decreased osteosarcoma cell proliferation, mainly due to an increase in apoptosis in a dose-depen...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Molecular cancer therapeutics 2007-12, Vol.6 (12), p.3263-3270
Hauptverfasser:	Dass, Crispin R, Choong, Peter F M
Format:	Artikel
Sprache:	eng
Schlagworte:	angiogenesis Animals apoptosis Base Sequence Bone Density Conservation Agents - pharmacology Cell Division - drug effects Cell Line, Tumor differentiation Diphosphonates - pharmacology DNA Primers Humans Imidazoles - pharmacology metastasis Mice Neoplasm Transplantation Osteoclasts - drug effects osteosarcoma Osteosarcoma - pathology zoledronic acid
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!